Syndax Pharmaceuticals (SNDX) Short-term Investments (2015 - 2026)

Syndax Pharmaceuticals' Short-term Investments history runs 12 years deep, the most recent figure standing at $221.2 million for Q1 2026.

• On a quarterly basis, Short-term Investments rose 5273.45% year-over-year to $221.2 million in Q1 2026; TTM through Mar 2026 was $221.2 million, a 5273.45% increase from a year earlier, with the FY2025 full-year figure at $19.6 million, up 95.59% from the prior year.
• Short-term Investments rose to $221.2 million in Q1 2026 per SNDX's latest filing, from $19.6 million in the prior quarter.
• Across five years, Short-term Investments topped out at $401.4 million in Q4 2022 and bottomed at $4.1 million in Q1 2025.
• The 5-year median for Short-term Investments is $18.2 million (2025), against an average of $124.4 million.
• Across the five-year window, Short-term Investments soared 348983.48% in 2022 and sank 98.71% in 2025, its largest moves.
• Year by year, Short-term Investments stood at $401.4 million in 2022, then tumbled by 31.42% to $275.3 million in 2023, then plunged by 96.36% to $10.0 million in 2024, then soared by 95.59% to $19.6 million in 2025, then jumped by 1027.5% to $221.2 million in 2026.
• Per Business Quant, the three latest SNDX Short-term Investments figures stand at $221.2 million (Q1 2026), $19.6 million (Q4 2025), and $18.2 million (Q3 2025).